A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Idelalisib (Primary) ; Lenalidomide (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2020, as reported by ClinicalTrials.gov.
- 16 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2017 as reported by ClinicalTrials.gov record.